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Inflammatory responses in the brain, which can be demonstrated by changes in properties of microglia, the
brain-resident macrophages, are a common feature of human neurodegenerative diseases. Different monocyte/
macrophage phenotypes have been defined by changes in expression of cytokines, receptors and other markers as
a response to different classes of stimuli. Monocytes, macrophages and microglia can have a range of phenotypes
with associated properties depending on their microenvironment. Macrophage/microglia polarization states have
been defined as classical activation (M1), alternative activation (M2a), type II alternative activation (M2b) or acquired
deactivation (M2c). Available markers for identifying microglial phenotypes in human brains are still limited; those
available provide incomplete information on the functions or polarization states of microglia observed in tissues
from diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. The most widely used marker
to describe activated microglia in human brains, particularly diseased brains, has been HLA-DR, the major
histocompatibility complex II protein. HLA-DR-positive microglia can have a wide range of activation morphologies
that are affected not only by disease pathology, but also by their differentiation states and brain regions. Two other
widely used markers to identify microglia in human brains are ionized calcium binding adaptor molecule-1 and
CD68. Although their expression changes in diseased brains, these markers do not show specificity for different
phenotypes. Over the years there have been studies with additional markers that attempt to further define
microglial properties, particularly in Alzheimer’s disease brains. Most studies have employed immunohistochemical
techniques to identify microglia in tissue sections, but recent advances in this field have allowed gene expression
profiling of microglia upon immediate isolation from brains. We will review which markers might better define
different activation phenotypes of microglia in human brains and whether they fit into current microglial
polarization schemes.Introduction
It has been more than a quarter-century since the “new
era” of studies of inflammation in Alzheimer’s disease
(AD) and Parkinson’s disease (PD) brains identified the
major histocompatibility complex class II (MHC-II) pro-
tein HLA-DR as a marker to identify “activated” micro-
glia. However, there are many features of microglia in
human neurodegenerative diseases that remain to be
understood [1–4]. Defining microglial properties in rela-
tion to neuropathology has generally required antibodies
that can be used to identify different types of microglia* Correspondence: douglas.walker@bannerhealth.com
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this article, unless otherwise stated.in fixed human tissue sections using immunohistochem-
istry techniques. Recently, gene expression profiling and
flow cytometry techniques of microglia isolated from
brain or excised from tissue sections have also been ap-
plied to address these issues [5, 6].
Initial human neuropathology studies promoted the
hypothesis that increased expression of HLA-DR by
microglia, particularly if combined with a hypertrophic
morphology and closely associated with pathological
structures, identified cells presumed to be causing in-
flammatory damage—by current definition, being clas-
sically activated or having an M1 phenotype (reviewed in
[2, 3]). Using appropriately fixed tissue samples and suit-
able monoclonal antibodies to HLA-DR, it was possiblerticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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ciated with amyloid plaques and neurofibrillary tangles,
the hallmark pathological structures of AD (reviewed in
[2]), free neuromelanin and dopaminergic neurons in
the substantia nigra (SN) of PD brains [7], or around
demyelinated plaques in brains from multiple sclerosis
(MS) cases [8]. Many additional studies have since used
antibodies to HLA-DR to confirm these findings in AD,
PD and MS brain tissues. HLA-DR-positive microglia
have also been observed in pathology-rich brain regions
in human neurodegenerative diseases such as dementia
with Lewy bodies (DLB) and frontal temporal dementia
(FTD) [9]. The close interactions of HLA-DR-activated
microglia with pathological structures suggested that
these abnormal protein structures were activating the
microglia, and also that these activated microglia might
be enhancing the pathological processes.
Questions remain about the functional significance of
HLA-DR expression by microglia. To illustrate this
point, Fig. 1 shows representative examples of HLA-DR-
positive microglia in a single AD temporal cortex section
that have morphologies ranging from highly ramified
(considered resting) to those with hypertrophic cell bod-
ies (considered activated and inflammatory). Data now
suggest that HLA-DR reactivity alone does not identify
microglial polarity or function since HLA-DR upregula-
tion can also be a feature of alternatively activated mi-
croglia/macrophages, which are microglia/macrophages
with anti-inflammatory reparative phenotypes [10]. ManyFig. 1 Various morphologies of microglia in human brain sections. Progres
pathology-rich section from an AD case. HLA-DR-expressing microglia can
ramified to c moderately hypertrophic to e highly activated with enlarged
Sections were stained using antibody LN3 (1:1,000 dilution; Abcam, Cambri
immunohistochemistry and counterstained with neutral redstudies have been published presenting results of im-
munohistochemistry with a range of different antigenic
markers identifying altered expression in microglia in
human brains affected by disease processes (key reviews
[2, 3]). These studies have substantially advanced the field
of neuroinflammation; these markers will be considered in
relation to the function of identified cells, as well as
how they fit into the context of microglial polarization
(Table 1).
Defining immune phenotypes of microglia and
macrophages
A range of profiling studies by Gordon and colleagues
identified what could be valid markers for classically or
alternatively activated human macrophages (key papers
[11, 12]). A scheme was developed that divided micro-
glia/macrophages into classically activated (M1) cells
based on changes in responses to the proinflammatory
agents lipopolysaccharide (LPS) and interferon gamma
(IFN-γ). M1 activated microglia can produce reactive
oxygen species as a result of reduced nicotinamide aden-
ine dinucleotide phosphate (NADPH) oxidase activation
(respiratory burst), and increased production of proin-
flammatory cytokines such as tumor necrosis factor
(TNF) alpha and interleukin (IL)-1β. These are the types
of microglia/macrophages that could be mediating in-
flammatory tissue damage.
Alternative activation (M2), as the other arm of this
scheme, was defined as the phenotype of microglia/sive changes in morphology of HLA-DR-expressing microglia in a
be found with various activation morphologies ranging from a highly
cell body and processes. b, d Intermediate changes in morphology.
dge, MA, USA) using nickel-enhanced diaminobenzidine peroxidase
Table 1 Selected immune function markers expressed by human microglia
Designation (references) M1 M2 AD brains
CD14 [15, 16] ++ – Vessels and around plaques
CD16, CD32, CD64 [13, 38] Uncertain ++ Increased on phagocytic microglia
CD45 [39, 40] ++ + All microglia: increase in disease
CD11b [49] Uncertain Uncertain Most microglia: increase in disease
CD68 [20] Uncertain Uncertain Increased on plaque microglia
CD163 [22] – ++ M2c: vessel-associated microglia
CD206 [34] – mRNA perivascular macrophages
CD209 [21] – ++ M2a: MS lesion-associated microglia
CCL22 [21] – ++ M2a: MS lesion-associated microglia
CD36 [18] Uncertain ++ Phagocytic microglia
Cyclooxygenase-1 [43] – ++ Plaque-associated microglia
TLR-2 [15] ++ + Plaque-associated microglia
Ferritin [41] ++ Uncertain Pathology-associated microglia
TREM2 [46] – + Plaque-associated microglia
CD33 [45] – + Increased expression in AD
CSF-1R [23] Uncertain Uncertain Increased expression in AD
There is uncertainty about the assignment of the protein markers to M1 or M2. These are based on the authors’ interpretation of different literature including data
from in vitro experiments. – to ++, observed changes in microglia in brain samples. Assignment based on in vitro findings. M2 includes M2a, M2b and M2c
AD Alzheimer’s disease, CSF-1R colony-stimulating factor-1 receptor, MS multiple sclerosis, TLR Toll-like receptor, TREM-2 triggering receptor expressed by
myeloid cells-2
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known as M2a. Microglia with M2a phenotypes have
increased phagocytosis and produce growth factors such
as insulin-like growth factor-1 and anti-inflammatory
cytokines such as IL-10 [10]. These types of microglia
could be removing cellular debris and promoting tissue
repair. The alternative activation scheme has been re-
fined into two further subcategories: M2b and M2c.
M2b (type II alternative activation) is induced by ligation
of immunoglobulin Fc gamma receptors (FcγRs) (CD16,
CD32 or CD64) by immune complexes on LPS or IL-1β
primed microglia/macrophages, which results in down-
regulated expression of IL-12, increased IL-10 secretion
and increased HLA-DR expression. This phenotype is
also characterized by increased expression of CD32 and
CD64, which has been described on microglia in AD
brains [13], and associated with increased phagocytic
activity. CD32 expression seems to be crucial for type II
activation to occur in human monocytes and macro-
phages. M2c (acquired deactivation) can be induced by
the anti-inflammatory cytokine IL-10 or glucocorticoids,
with increased expression of transforming growth factor
(TGF) beta, sphingosine kinase (SPHK1) and CD163, the
membrane-bound scavenger receptor for haptoglobin/
hemoglobin complexes [14].
Microglia in human brains
Markers used to describe microglia in human brains in-
clude CD14 [15, 16], CD40 [17], CD16, CD32 and CD64(the three classes of immunoglobulin Fc receptors) [13],
phagocytic receptors (CD36) [18] and macrophage scav-
enger receptor MSR-A [19], CD68 (a lysosomal marker
indicative of phagocytic activity of microglia, example
[20]), CD74, CD86 and C–C chemokine ligand CCL22
[21], CD163 [22] and macrophage colony-stimulating
factor-1 receptor (CSF-1R; CD115) [23]. How these
markers might fit into the M1 or M2 classification
scheme is suggested in Table 1. A common feature
described for most of these markers has been increased
expression on hypertrophic microglia associated with
pathology; however, it is now appreciated that a whole
spectrum of microglial phenotypes and morphologies
can be present within a human brain (Fig. 1) [24]. Micro-
glia can be at different stages of differentiation, activation
and function in tissue, but currently used markers do not
show these features.
CD40 has been consistently shown to be a marker for
M1 activation of macrophages/microglia [17]. In AD
brains, widespread expression of CD40 by microglia has
been observed; however, it was noted that increased
microglial CD40 expression was only prominent in AD
brains with other disease factors such as bacterial
encephalitis [17]. These findings do suggest that AD
pathology alone might not be sufficient to induce M1 ac-
tivation and significant CD40 expression. An interesting
question remaining is what do M2 microglia look like in
human brain tissue, and how different are they morpho-
logically from M1 microglia? A recent study examining
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and C–X–C chemokine ligand CXCL10 as markers of
M1 activation, and CCL22 and CD209 (DC-SIGN) as
M2a markers [21]. In this study, mixed populations of
microglia with both M1 and M2 phenotypes were
observed in diseased brain tissue. For example, CCL22
immunoreactive microglia were also CD40-positive and
HLA-DR-positive. The ability of microglia to transition
between M1 and M2a phenotypes was demonstrated
in vitro in this study. It is worth noting that this study
could not demonstrate microglia immunoreactive for
CD206, a prototypical M2a marker [21]. CD206 im-
munoreactivity was only observed in macrophages
present in vessels. These findings indicate the need
for validation of CCL22 as a genuine marker for M2a
in human microglia.
In studies of M1 and M2 markers in RNA samples ex-
tracted from AD brains, coexpression of M1, M2a, M2b
and M2c markers could be detected in samples [25, 26].
However, one limitation to this approach that affects all
human tissue studies is that gene expression intensities
might include mRNA from monocytes/macrophages
present within the brain blood vessels. Comparing gene
expression profiles of M1 and M2a human macro-
phages identified C–C chemokine receptor CCR7, IL2Ra,
IL15Ra, chemokines CXCL11, CCL19, CXCL10 and
CXCL9 and indoleamine-pyrrole-2,3-dioxygenase as the
best M1 markers, with P2Y5 purinergic receptor, C-type
lectin receptors DCL-1 and DECTIN1, CD209, macro-
phage mannose receptor and chemokines CCL13, CCL18
and CCL23 as markers of M2a alternative activation [12].
This landmark paper identified many markers for blood
macrophages but indicated targets for study in human
microglia. Antibodies to most of these markers have still
not been tested to determine whether they identify micro-
glia in human brains. One other marker identified in this
study [12] is CD36, which has been studied in AD brains
and identifies plaque-associated microglia. CD36 is a
phagocytic scavenger receptor for amyloid beta peptide
(Aβ) [18], but has been defined as an M2a alternative acti-
vation marker for human macrophages [12].
Another widely used marker for microglia in tissues is
ionized calcium binding adaptor molecule-1 (IBA-1),
which interacts with actin bundles and is involved with
membrane ruffling and phagocytosis [27]. IBA-1 has the
same sequence as allograft inflammatory factor-1 (AIF-1).
This protein can be demonstrated in all microglia with
some increase in expression and cellular rearrangement in
activated microglia. Its applicability as an activation
marker is still unresolved; a semiquantitative analysis
of microglia in the SN of PD and incidental Lewy
body disease (ILBD) cases compared with controls
showed a slight increase in IBA-1 immunoreactivity,
but a large progressive increase in CD68, a markerfor actively phagocytic microglia [28]. As IBA-1 appears to
identify all microglia, it is not useful for identifying their
immune phenotype/polarity [27]. This was also demon-
strated in tissue sections from AD cases that had received
the Aβ peptide vaccine as treatment, which resulted
in significantly increased phagocytosis of Aβ by mi-
croglia [29]. Comparing the microglia load (IBA-1 reactiv-
ity) between control and immunized cases showed no
overall difference in microglial numbers, but, by con-
trast, microglial markers associated with phagocytosis
(CD68, CD32, CD64 and macrophage scavenger re-
ceptor MSR-A) were significantly reduced in the im-
munized cases where Aβ removal had occurred [20].
These data demonstrate how levels of expression of
certain markers can change depending on the functional
state of microglia.
Investigation of microglial phenotypes in human
brains
The investigation of polarization markers expressed by
microglia in the brain has been extended from immu-
nohistochemistry techniques with antibodies to gene
expression profiling and flow cytometry methodology of
microglia directly extracted from human brains [6, 30–32].
Phenotyping studies of ex vivo brain isolated microglia
have utilized postmortem human brain white matter in
relation to studies of MS [6, 30] or surgical samples of
temporal cortex resected as treatment for epilepsy [31];
however, these findings have relevance to all neurode-
generative diseases with microglial components. In one
of these studies, ex vivo isolated microglia from white
matter showed positive reactivity to HLA-DR, CD16,
CD32 and CD64, but not to CD14, CD80, CD163,
CD200 receptor (CD200R) or CD206 [6]. This result is
not indicative of either an M1 or an M2a phenotype.
Microglia derived from white matter from MS cases
showed the same profile, but with significantly increased
expression of CD14, suggesting a higher proportion
having an M1 phenotype [30]. Further confirming the
limited M1 phenotype of freshly isolated microglia,
when these cells were put into culture they exhibited
limited responses to LPS/IFN-γ [30]. By comparison,
similarly prepared and cultured microglia could mount
strong M2a and M2c responses when treated with IL-4
or glucocorticoid, respectively [6, 30]. In these studies,
it was illustrated that human brain microglia cultured
for up to 4 days showed progressive increased expres-
sion of CD14 [6, 31], while measurements of Toll-like
receptor TLR-4 or IFN-γ receptor expression did not
show this response. In a gene expression profiling study,
we have shown that human microglia in culture demon-
strated an acute M1-like response to 2 μM aggregated
Aβ(1–42) after 24 hours of treatment [33]. Many of the
genes associated with M2 responses or phagocytosis
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ing microglia that is being explored involves laser cap-
ture microdissection (LCM) of microglia from brain
tissue sections followed by gene expression profiling.
LCM has been widely used to dissect out discrete
populations of neurons, astrocytes and endothelial
cells from intact tissue sections; these techniques are
also applicable for microglia [5]. One advantage of ex-
pression profiling methods for characterizing micro-
glia is that they permit studies of genes not readily
amenable to antibody staining (e.g., soluble chemokines/
cytokines).
The morphology of HLA-DR immunoreactive micro-
glia, with their close interaction with disease-associated
cellular structures in AD brains, suggests a classical acti-
vation phenotype. It is noticeable that only a subset of
these microglia in AD brains appears to be phagocytic.
Contrary to what is observed in PD, where phagocytosis
by microglia of neuromelanin can be seen, or in MS,
with phagocytosis of myelin, observing microglia phago-
cytosis of Aβ in AD tissue sections is not as common
even though there is a microglial “response” to plaques.
Differences in microglia properties have been defined in
neuropathology studies of subjects that had been immu-
nized with amyloid peptides as part of experimental
treatments [20, 29]. It has been suggested that classically
activated microglia actually show reduced phagocytosis.
The Aβ immunization strategy highlights this with the
need for Aβ to be complexed with antibodies to promote
polarization to a phagocytic phenotype. The interaction
of immune complexes with primed microglia is a feature
of M2b activated microglia.
An unanswered question is whether there are M2a or
other alternatively activated microglia in AD or PD brains.
There have been no reports demonstrating localization of
markers of M2a alternative activation markers on micro-
glia in AD or PD brains, even though increased expression
of M2a markers CD206 and arginase-1 could detected by
mRNA expression in AD tissue samples [26, 34]. There is
a need to be able to distinguish by location between mac-
rophages, which can be abundant in blood vessels of the
brain, and microglia in the neuropil. CD200R, a new
marker for M2a activation for microglia or macrophages,
could also not be immunolocalized to microglia in AD
tissue samples, even though mRNA expression was de-
tectable [35]. CD200R immunoreactivity could only be
detected in vascular macrophages in normal or MS tissue
[21, 36]. Similarly, expression of CD200R in ex vivo
isolated microglia was virtually undetectable even though
expression was readily detectable in similarly isolated
macrophages [36, 37]. These findings suggest that micro-
glia with M2a phenotype are rare in AD brains. The iden-
tification of the most suitable marker for M2a in human
tissues is still undecided. In MS tissues, immunoreactivityon lesion-associated microglia was observed for CCL22
and CD209, but not for CD206 [21].
Possible immune phenotype markers besides
MHC-II and IBA-1
Table 1 presents some of the markers that have been
reported in (primarily) human AD tissues to identify dif-
ferent features of microglia. Specific features of several
of these markers are discussed below.
CD14
CD14 (LPS receptor) has been used in flow cytometric
analyses to discriminate degrees of activation in macro-
phages and microglia. To some, CD14 has been consid-
ered a constitutive macrophage marker that all microglia
will be expressing; however, in populations of monocytes/
microglia, high or low expression of CD14 has been useful
to define levels of activation [6]. Surprisingly, there have
been only two studies that characterize cellular loca-
lization of CD14 expression in microglia in human
AD-affected brains [15, 16]. CD14 antibody stains blood
monocytes in brain vessels abundantly, and a very small
percentage of plaque-associated microglia.
Immunoglobulin Fc receptors (CD16, CD32 and CD64)
There are multiple types of the FcγR family expressed by
macrophages and microglia. These include CD64 (FcγRI),
CD16a (FcγRIIIA) and CD16b (FcγRIIIB) that activate
proinflammatory signaling, and CD32a (FcγRIIA) and
CD32b (FcγRIIB) that activate inhibitory signaling. All of
these receptors can be considered phagocytic. Increased
expression of these receptors has been associated with ac-
quisition of the M2b phenotype, which has overlap with,
but distinct differences from, gene profiles of M1 and M2a
[26]. Microglia expressing CD16, CD32 and CD64 have
been described in AD brains with increased levels of ex-
pression in pathology-associated microglia [13, 38].
CD45
The usefulness of phenotyping human brain microglia for
CD45 (leucocyte common antigen) is unclear because this
marker appears to identify all microglia in human brains,
but there are increased levels in AD pathology-associated
microglia [39]. Phenotyping of microglia for CD45 imme-
diately after their isolation from human brain tissues
showed lower levels than in macrophages, while white
matter microglia had higher CD45 expression than gray
matter cells, with microglia from MS brains having in-
creased CD45 expression compared with control brains
[39, 40]. Treatment of ex vivo isolated microglia with LPS,
IFN-γ, IL-4 or dexamethasone—the stimuli for inducing
M1, M2a or M2c polarity, respectively—did not induce
CD45 expression.
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One of the most useful and descriptive markers for micro-
glial function has been CD68 (macrosialin in mice). This
protein is localized to the lysosomal membrane in micro-
glia and monocytes, and is upregulated in actively phago-
cytic cells [20]. Both M1 polarized and M2 polarized
microglia/macrophages can express CD68 [11].
Ferritin
Antibodies to L-ferritin selectively identify classes of
microglia in human brain tissue sections [41]. Ferritin is
the most abundant carrier protein for iron in the brain.
Increased expression of ferritin associated with increased
iron uptake seems associated with microglia undergoing
proinflammatory responses and reactive oxygen species
production, which is dependent on iron. Ferritin has been
used to describe a dystrophic and degenerating phenotype
of microglia, but their immune phenotype is unclear [42].
Cyclooxygenase-1 and cyclooxygenase-2
Cyclooxygenase (Cox)-1 and Cox-2 have been favored
targets for anti-inflammatory therapy for AD, but with
limited beneficial results. Although associated with in-
flammation, Cox-2 has not been observed in microglia
in AD brains, while Cox-1 has been localized to micro-
glia associated with plaques [43]. Increased expression of
Cox-1 in human macrophages has been characterized as
an M2a response [11].
CD33
CD33 (Siglec-3) is a sialic acid activated receptor whose
expression is generally restricted to myeloid cells. CD33
is expressed on microglia in human brains [44, 45].
Intense interest in this marker has come from the identi-
fication of a single nucleotide polymorphism (SNP
rs3865444) adjacent to the CD33 coding region being
associated with altered risk of developing AD (odds
ratio −0.89). Possession of the protective SNP results
in reduced levels of CD33 in human brains [44, 45]. Our
findings suggest that CD33 is constitutively expressed on
microglia with increased levels on hypertrophic microglia.
The regulation of CD33 expression by microglia has not
been defined so it is not clear whether this marker reflects
the M1 or M2 phenotype. Owing to anti-inflammatory
signaling properties, CD33 and related sialic acid binding
receptors have been suggested to polarize microglia to-
wards an M2 phenotype; however, our in vitro data with
human microglia showed that CD33 mRNA expression
was not induced by LPS or IFN-γ (M1 stimuli) or by IL-4
(M2a stimulus) [45].
Triggering receptor expressed by myeloid cells-2
Another microglial protein that has been associated with
altered risk of AD is the triggering receptor expressed bymyeloid cells-2 (TREM-2), where the mutation R47H in
the coding sequence (SNP rs75932628) is associated
with increased risk of AD. We have observed that there
is increased expression of nonmutated TREM-2 on
plaque-associated microglia in AD brains, with increased
levels in AD tissues compared with control tissue [46].
There are insufficient data to indicate whether increased
TREM-2 can be considered as a M1 or M2a activation
marker in human microglia. Functionally, the marker
appears similar to M2a anti-inflammatory receptors.
CCL22 (monocyte-derived chemokine)
One recent study which defined CCL22 as an M2a
marker by showing increased secretion by cultured hu-
man microglia in response to IL-4 also demonstrated
microglia associated with MS lesions as having CCL22
immunoreactivity. These microglia were also immunore-
active for HLA-DR [21].
Should we be defining an “M3” phenotype?
A potential limitation to the M1 or M2 immune phenotyp-
ing scheme is that it seems to omit microglia undergoing
cell division as a response to macrophage colony-
stimulating factor CSF-1 or the recently identified IL-34.
Cell division by microglia can be considered an ongoing
feature of microglia in pathology-rich areas, and is re-
quired to replace these short-lived cells. Both cytokines
signal through the same macrophage/microglia receptor
(CSF-1R) and not only induce cell division of microglia
and critically affect their development, maturation and
survival [47]. Examination of CSF-1R immunoreactivity of
microglia in humans is limited to a single study that dem-
onstrated a certain level of expression in control brains
with increased expression in AD brains, especially in
microglia accumulated around plaques [23]. Recent find-
ings suggest that macrophage colony-stimulating factor-
treated microglia have neither an M1 or M2a polarization
state [48], although other works have classified CSF-1R
signaling as similar to M2a activation [10].
Conclusions
Until we have the reagents to detect microglial activities
in human brain tissues associated with immune pheno-
types and function, for example the production of reactive
oxygen species or secretion of cytokines, a panel of anti-
genic markers that can be used to assign phenotype and
function to identified microglia would be useful. Many of
the initial papers describing microglial markers are now
dated, but certain of these need to be reexamined in the
context of understanding current concepts of phenotype.
In addition, more recent papers describing profiling of
human macrophages and microglia have identified new
markers that can be applied to immunohistochemistry of
diseased brain tissue if suitable antibodies are available.
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used to describe microglia and others that can be used
to define their different phenotypes. The literature does
have some conflicting results for certain of these markers;
in some cases, there is discrepancy between mRNA and
protein data.
Some of the publications on microglia markers have
come about as a result of the availability of antibodies
that react well with fixed human brain tissues. Many
antibodies available to these discussed markers do not
react with antigens fixed according to routine pathology
procedures.
Although there are other candidates that can be re-
examined, we propose that CD14, the LPS receptor, has
been underappreciated as a functional activation marker
of microglia. CD14 seems to be a sensitive marker for
primed microglia, because levels of expression in microgliaFig. 2 Possible markers for microglial phenotyping in human brains. Schem
different microglial phenotypes in human brains. Data show some markers
markers whose function is suggestive of polarity (e.g., CD200R, CD33 and T
C–C chemokine ligand, CD200R CD200 receptor, CSF-1R colony-stimulating
IFN-γ interferon gamma, IL interleukin, LPS lipopolysaccharide, TGF transformin
expressed by myeloid cells-2newly isolated from the human brain [6, 30–32] are very
low but are higher in diseased MS brains [30]. High levels
of CD14 in macrophages correspond to immune activa-
tion, but expression is suppressed in the brain; however,
with the appropriate antibody we are reexamining the
identification of CD14-positive microglia (in preparation,
Walker and Lue, 2015), where positive reactivity must
have some specific activation state. It was already known
that only a small subset of microglia around plaques was
immunoreactive in AD brains [16]. Freshly isolated micro-
glia from nondiseased brain show very weak response to
LPS, probably due to low levels of CD14 and TLR4
expression. Increased pattern expression of CD14 in
microglia in diseases could be informative to describing
M1 activated microglia.
In conclusion, it may be a hard task to bring together
the fundamental findings of immunologists and celle to illustrate different markers that could be used for identifying
that have been applied from more than one study. We include
REM-2) but not proven with published data for human microglia. CCL
factor-1 receptor, IBA-1 ionized calcium binding adaptor molecule-1,
g growth factor, TNF tumor necrosis factor, TREM-2 triggering receptor
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ticing neuropathologists, on the other, but the poten-
tial could be to make discoveries on how and where
inflammation is actually causing neurodegeneration
(or neuroregeneration). From such observations, new
disease-modifying molecular targets can evolve.Note: This article is part of a series on Innate Immunity, edited
by Donna Wilcock. Other articles in this series can be found at
http://alres.com/series/innateimmunityAbbreviations
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